Oral Delivery of Exenatide via Microspheres Prepared by Cross-Linking of Alginate and Hyaluronate

Baojie Zhang, Dongyang He, Yu Fan, Nan Liu*, Yijun Chen*

State Key Laboratory of Natural Medicines and Laboratory of Chemical Biology, China Pharmaceutical University, Nanjing, China

Abstract

Exendin-4 containing 39 amino acid residues was originally isolated from Helodermatidae venom. This peptide shares 53% sequence homology with glucagon-like peptide-1 (GLP-1) [1]. Given that exendin-4 can compete with GLP-1 for the same binding site in mammalian cells with higher affinity and stronger resistance to the degradation by dipeptidyl peptidase IV (DPP-IV), exendin-4 exhibits obvious advantages to be developed as a glucose-lowering agent with similar functions as GLP-1 [1–3].

Subsequently, exenatide, the synthetic version of exendin-4, was approved by the FDA in 2005 as adjunctive therapy to improve glucose homeostasis in type 2 diabetic patients [4]. However, the twice daily subcutaneous injections have posed clear shortcomings, such as inconvenience for the administration, local pain and irritation during the injection [5]. Therefore, it is favorable for exenatide to mimic physiological route of GLP-1 from intestine to circulation to avoid potential side effects [6]. Consequently, the development of a non-injective route for exenatide delivery has drawn great interests by both industry and academia, and oral administration is an ultimate choice based on the easy acceptance the absorption of the macromolecules by intestinal epithelium are the key challenges to deliver these drugs by oral administration. Despite significant developments in oral delivery technologies, successful oral delivery of protein or peptide drugs remains very limited. To address various issues associated with oral administration of macromolecule drugs, different approaches have been attempted in recent years, including chemical modifications by substitution, acylation or PEGylation to alter their physicochemical properties, the addition of other novel functions and the use of more efficient delivery carriers [10]. Among these approaches, biotinylation of exendin-4 reported by Jin et al achieved 3.95% apparent bioavailability after oral administration [11]. Meanwhile, modification of exenatide with PEG (20 kDa – 40 kDa) resulted in prolonged plasma half-time to approximately 1 h via subcutaneous injection [12]. More recently, a pH-sensitive nanoparticle system composed of chitosan and poly-(γ-glutamic acid) was developed for oral delivery of exendin-4. However, the self-assembled nanoparticles were not stable in stomach. Although the subsequent filling of the exendin-4 loaded nanoparticles in enteric-coated capsules could deliver sufficient amount of exendin-4 into the circulation, it took 8 h for the drug to be effective on lowering glucose level in animals [13]. This suggested that the delayed effects of this delivery system are not suitable for clinical application. To overcome these disadvantages and become more clinically relevant, different from previous approaches, we therefore chose chemical cross-linking of alginate and hyaluronate aiming to prepare exenatide-encapsulated microspheres for more effective oral delivery of exenatide.

Introduction

Exendin-4 containing 39 amino acid residues was originally isolated from Helodermatidae venom. This peptide shares 53% sequence homology with glucagon-like peptide-1 (GLP-1) [1]. Given that exendin-4 can compete with GLP-1 for the same binding site in mammalian cells with higher affinity and stronger resistance to the degradation by dipeptidyl peptidase IV (DPP-IV), exendin-4 exhibits obvious advantages to be developed as a glucose-lowering agent with similar functions as GLP-1 [1–3].

Subsequently, exenatide, the synthetic version of exendin-4, was approved by the FDA in 2005 as adjunctive therapy to improve glucose homeostasis in type 2 diabetic patients [4]. However, the twice daily subcutaneous injections have posed clear shortcomings, such as inconvenience for the administration, local pain and irritation during the injection [5]. Therefore, it is favorable for exenatide to mimic physiological route of GLP-1 from intestine to circulation to avoid potential side effects [6]. Consequently, the development of a non-injective route for exenatide delivery has drawn great interests by both industry and academia, and oral administration is an ultimate choice based on the easy acceptance the absorption of the macromolecules by intestinal epithelum are the key challenges to deliver these drugs by oral administration. Despite significant developments in oral delivery technologies, successful oral delivery of protein or peptide drugs remains very limited. To address various issues associated with oral administration of macromolecule drugs, different approaches have been attempted in recent years, including chemical modifications by substitution, acylation or PEGylation to alter their physicochemical properties, the addition of other novel functions and the use of more efficient delivery carriers [10]. Among these approaches, biotinylation of exendin-4 reported by Jin et al achieved 3.95% apparent bioavailability after oral administration [11]. Meanwhile, modification of exenatide with PEG (20 kDa – 40 kDa) resulted in prolonged plasma half-time to approximately 1 h via subcutaneous injection [12]. More recently, a pH-sensitive nanoparticle system composed of chitosan and poly-(γ-glutamic acid) was developed for oral delivery of exendin-4. However, the self-assembled nanoparticles were not stable in stomach. Although the subsequent filling of the exendin-4 loaded nanoparticles in enteric-coated capsules could deliver sufficient amount of exendin-4 into the circulation, it took 8 h for the drug to be effective on lowering glucose level in animals [13]. This suggested that the delayed effects of this delivery system are not suitable for clinical application. To overcome these disadvantages and become more clinically relevant, different from previous approaches, we therefore chose chemical cross-linking of alginate and hyaluronate aiming to prepare exenatide-encapsulated microspheres for more effective oral delivery of exenatide.

Abstract

Exendin-4 containing 39 amino acid residues was originally isolated from Helodermatidae venom. This peptide shares 53% sequence homology with glucagon-like peptide-1 (GLP-1) [1]. Given that exendin-4 can compete with GLP-1 for the same binding site in mammalian cells with higher affinity and stronger resistance to the degradation by dipeptidyl peptidase IV (DPP-IV), exendin-4 exhibits obvious advantages to be developed as a glucose-lowering agent with similar functions as GLP-1 [1–3].

Collectively, the present study demonstrated the feasibility of orally delivering exenatide with the new cross-linked biomaterial and formulation, and showed therapeutic potential for clinical applications.

Citation: Zhang B, He D, Fan Y, Liu N, Chen Y (2014) Oral Delivery of Exenatide via Microspheres Prepared by Cross-Linking of Alginate and Hyaluronate. PLoS ONE 9(1): e86064. doi:10.1371/journal.pone.0086064

Editor: Nigel Irwin, University of Ulster, United Kingdom

Received September 20, 2013; Accepted December 9, 2013; Published January 21, 2014

Copyright: © 2014 Zhang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the grants from the “111” Project from the Ministry of Education of China, and the State Administration of Foreign Export Affairs of China (No: 111-2-07), National Science and Technology Major Projects of China (2012ZX09103-101-030) and the Research Project of State Key Laboratory of Natural Medicines, China Pharmaceutical University (No: SKLNZZCZX201301). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: liunan0428@aliyun.com (NL); yjchen@cpu.edu.cn (YC)
As biodegradable anion polysaccharides, both alginate and hyaluronate have been widely used to encapsulate various drugs for controlled release and targeted drug delivery [14,15]. In addition to the naturally occurring and nontoxic properties, alginate and hyaluronate possess pH-responsive characteristics. Typically, they can keep compact in acidic solution while be swelled in alkaline condition. These two environments can mimic the situations of stomach and small intestine respectively. According to their special characteristics, any compounds loaded by alginate or hyaluronate could presumably be protected in stomach and be released in small intestine. Surprisingly, when alginate and hyaluronate were simply mixed together, they were unable to self-assembly organized because of the repulsion between these two materials. Therefore, cross-linking of alginate and hyaluronate by chemical method could generate a novel material that synergistically maintains respective pH-responsive-ness and the capability of encapsulating exenatide. After preparation of exenatide-loaded microspheres by cross-linking of alginate and hyaluronate, in vitro releases in the conditions mimicking gastrointestinal pH environments, in vivo pharmacokinetics (PK) and glucose-lowering effects in db/db mice were performed and compared. The results indicated that the exenatide-loaded microspheres could effectively deliver the drug to lower plasma glucose level after oral administration.

Materials and Methods

1. Ethics statement
All experimental animals were cared according to the guidelines of National Institute of Health (NIH), and animal studies were reviewed and approved by the Ethical Committee on Animal Experimentation of China Pharmaceutical University.

2. Materials
Sodium alginate (Mw: approx.180 kDa, pharmaceutical grade) was a gift from Huanghai Biological Pharmaceutical Co. Ltd (Qingdao). Sodium hyaluronate (Mw: 1,955 kDa, pharmaceutical grade) was purchased from Freda Biotechnology Co. Ltd (Shandong). Exenatide was from GL Biochem Ltd (Shanghai). Blood glucose meter and test strips were purchased from Johnson & Johnson Company (USA). Bicinchoninic acid (BCA) protein assay kit was purchased from Phoenix Pharmaceuticals Inc. (USA). Exendin-4 enzyme immunoassay kit (EK-070-94) was purchased from Phoenix Pharmaceuticals Inc. (USA). Sorbic acid (SA) and hyaluronate (Mw: 1,955 kDa, pharmaceutical grade) was purchased from Freda Biotechnology Co. Ltd (Qingdao). Sodium alginate (Mw: approx.180 kDa, pharmaceutical grade) was purchased from Generay Biotech Co. Ltd (Shanghai). All other chemicals were pharmaceutical grade and commercially available.

3. Animals
C57BL/16J db/db mice (male, 8–12 weeks) were purchased from Cavers Lab Animal Co. Ltd (Changzhou). According to the guidelines of NIH, animals were housed in the specific pathogen free (SPF) laboratory with clean sawdust. Mice were grouped 5 animals per cage and raised under 12 hours light or dark cycle, allowed water and food ad libitum which were replaced frequently to keep fresh. Cages and bottles were cleaned twice a week with changing new sawdust when necessary. After 2-week acclimatization, animal studies were performed and minimization of animal sufferings was undertaken during the experiments. Mice were gently grasped and quickly administered the drugs using smaller syringe or blood sample were extracted by thinner capillary tube. In the end of the experiments, mice were sacrificed between 5-8 weeks after the experiments by removal of cervical spine.

4. Preparation of exenatide-loaded microspheres
The dispersed phase consisting of 75 mg sodium alginate, 25 mg sodium hyaluronate and 3 mg exenatide was dissolved in 5 ml purified water and prepared by magnetic stirring at 400 rpm for 30 min. Then, it was supersonically vibrated for 20 min and held for 1 h to remove the bubbles. Afterward, 10 ml paraffin liquid, the continuous phase, was blended with 2.5% (v/v) Span-80 for 30 min at 200 rpm. Under magnetic agitation at 400 rpm, the dispersed phase was dropped into continuous phase at a speed of 2 drops per second from a needle tube to form droplets. After 30 min, 5 ml 1 N HCl and 5 ml 25% glutaraldehyde (GTA) were added to mediate the cross-linking of alginate and hyaluronate at 40°C and the formation of solid microspheres. Finally, the exenatide-loaded microspheres were washed with ethanol, harvested by filtration under reduced pressure and dried overnight at room temperature.

5. Characterization of the microspheres
The blank microspheres were characterized with scanning electronic microscope (SEM, S-3400N, Hitachi, Japan). Residual amount of GTA in the microspheres was analyzed by GC (column: HP-5; instrument: Agilent 6890 Series GC system), in which both GTA sample (0.01%) and the microsphere sample (10 mg/ml) were measured with a temperature gradient. Briefly, initial temperature was 100°C and maintained for 1 min, then rose to 180°C at the speed of 10°C per min and held for 30 min. Finally, the column was kept at 280°C for 5 min. Temperatures of sample injector and detectors were 210°C and 250°C respectively.

The drug loading efficiency (LE) and loading content (LC) of the microspheres were determined by the amount of free exenatide remained in the supernatant using BCA protein assay kit [16] and calculated using the following equations [13]:

\[
LE(\%) = \frac{\text{total amount of exenatide added} - \text{free exenatide}}{\text{total amount of exenatide}} \times 100\%
\]

\[
LC(\%) = \frac{\text{total amount of exenatide added} - \text{free exenatide}}{\text{weight of microspheres}} \times 100\%
\]

6. Accumulative releases of exenatide
To simulate the environments of stomach and small intestine, 100 mg exenatide-loaded microspheres were distributed in 10 ml of 0.063 N HCl solutions (pH 1.2) for 2 h followed by transferring to 10 ml of 0.1 M sodium phosphate solution (pH 7.4) at 37°C. A solution of 500 μl was exactly pipeted from the upper layer every 1 h and filtered. At the same time, 500 μl of fresh warmed sodium phosphate buffer was added into the original solution. Exenatide in the supernatant was detected by BCA kit.

Swelling ratios (SR) at different time periods were investigated. Free water remained on the surface of swelled microspheres was dried by filtration under reduced pressure and SR was calculated as following [17]:

\[
SR(\%) = \frac{M_T - M_0}{M_0} \times 100\%
\]
oral administration as a negative control group; exenatide-loaded microspheres blended with free exenatide solution (500 µg/kg) via oral administration as a negative control group; exenatide-loaded microspheres (500 µg/kg) via oral administration as an experimental group; and free exenatide solution (50 µg/kg) via subcutaneous injection (SC) as a positive control group. To blend blank microspheres and free exenatide, exenatide was firstly dissolved in physiological saline, and blank microspheres were added to this solution to form a mixture. Each group contained 8 db/db mice. Blood samples were collected from the tail veins of mice prior to experiments and every 1 h or 2 h during the study, and blood glucose concentrations were measured by glucose meter.

To analyze the concentration of exenatide in plasma at different time points, blood samples were drawn from orbital sinus of mice and centrifuged (5000 rpm, 4°C for 45 min) prior to experiments and at predetermined intervals of 1 or 2 h during the experiments. The plasma concentration of exenatide was quantified with exendin-4 ELISA kit. The relative bioavailability (BAR) of the dispersed phase was defined as P < 0.05.

### Results and Discussions

#### 1. Preparation of exenatide-loaded microspheres

Microspheres were produced by initial emulsion and then suspended in GTA solution for cross-linking [18]. After dissolution of alginate, hyaluronate and exenatide in the dispersed phase, the resulting mixture was dropped into the continuous phase to form microspheres. As shown in Table 1 and Table 2, mass ratio of alginate and hyaluronate to be 3:1 and concentration of the dispersed phase to be 20 mg/ml resulted in the best productivity of the microspheres and loading efficiency. According to previous report, if the dispersed phase dissolved evenly in the continuous phase, the formed microspheres would have a uniform appearance. Thus, the proportion between the dispersed and continuous phases was a key factor [19]. In our case, the examination of the ratio of dispersed phase to continuous phase in three different groups resulted in similar productivity and loading efficiency. Therefore, we chose the ratio of 5:10 for subsequent experiments to minimize the use of paraffin liquid. Since surfactant was able to reduce the surface tension of continuous phase, an appropriate surfactant was chosen based on the hydrophilicity-lipophilicity balance (HLB). Given the fact that the type and amount of surfactant could significantly affect the drug loading and release behaviors of the microspheres [20], 2.5% Span-80 was identified to achieve the best loading efficiency (Table 3 and Table 4).

To cross-link alginate and hyaluronate, GTA, a widely used and effective cross-linking agent was used to form a hemiacetal between alginate and hyaluronate in the presence of HCl [21]. Because the degree of cross-linking increased with longer exposure time to GTA [22], we prepared three different types of microspheres by changing GTA reaction time as 0.5 h, 1 h and 2 h. Subsequently, comparison of different reaction time resulted in significantly different release behaviors due to the changes in size and appearance of the microspheres. As shown in Table 5, the microspheres prepared by using 1N HCl and 5 ml GTA at 40°C exhibited extended release of exenatide and gave the best

### Table 1. Comparison of different dispersed phase.

| Dispersed phase (mg/ml) | 40 | 20 | 10 |
|------------------------|----|----|----|
| Productivity (%)       | 63.3±0.85 | 68.7±1.71 | 64.3±0.98 |
| LE (%)                 | 58.3±2.98 | 72.9±1.57 | 69.8±0.84 |

*a*Data are averages of three independent experiments with standard deviations. doi:10.1371/journal.pone.0086064.t001

### Table 2. Comparison of different mass ratio between alginate and hyaluronate.

| Alginate:Hyaluronate (w/w) | 1:1 | 1:2 | 2:1 | 3:1 |
|----------------------------|-----|-----|-----|-----|
| Productivity (%)           | 58.2±1.91 | 50.1±1.19 | 61.4±0.74 | 67.9±1.33 |
| LE (%)                     | 60.7±0.74 | 55.4±1.54 | 64.5±2.64 | 70.9±1.71 |

*a*Data are averages of three independent experiments with standard deviations. doi:10.1371/journal.pone.0086064.t002

### Table 3. Comparison of volume ratio between dispersed phase and continuous phase.

| Dispersed phase: Continuous phase (v/v) | 5:50 | 5:25 | 5:10 |
|----------------------------------------|------|------|------|
| Productivity (%)                       | 63.8±2.12 | 64.7±0.69 | 64.2±1.17 |
| LE (%)                                 | 72.1±0.59 | 70.4±1.75 | 71.6±0.87 |

*a*Data are averages of three independent experiments with standard deviations. doi:10.1371/journal.pone.0086064.t003

### Table 4. Comparison of different surfactant concentration.

| Surfactant Concentration (%) | 0.5 | 1.0 | 2.5 | 5.0 |
|------------------------------|-----|-----|-----|-----|
| Productivity (%)             | 65.4±1.62 | 65.5±2.94 | 66.7±0.57 | 61.7±2.45 |
| LE (%)                       | 60.3±2.94 | 66.7±2.41 | 72.1±1.65 | 71.7±0.49 |

*a*Data are averages of three independent experiments with standard deviations. doi:10.1371/journal.pone.0086064.t004

where AUC represents the area under the curve of plasma exenatide concentration versus time.

### 8. Statistical analysis

Data were shown as mean ± standard deviation (SD). Comparison between two groups was analyzed by two-tail t-test

where MT is the weight of swelled microspheres and M₀ is the weight of initial dry microspheres.

### Table 3. Comparison of volume ratio between dispersed phase and continuous phase.

| Dispersed phase: Continuous phase (v/v) | 5:50 | 5:25 | 5:10 |
|----------------------------------------|------|------|------|
| Productivity (%)                       | 63.8±2.12 | 64.7±0.69 | 64.2±1.17 |
| LE (%)                                 | 72.1±0.59 | 70.4±1.75 | 71.6±0.87 |

*a*Data are averages of three independent experiments with standard deviations. doi:10.1371/journal.pone.0086064.t003

### Table 4. Comparison of different surfactant concentration.

| Surfactant Concentration (%) | 0.5 | 1.0 | 2.5 | 5.0 |
|------------------------------|-----|-----|-----|-----|
| Productivity (%)             | 65.4±1.62 | 65.5±2.94 | 66.7±0.57 | 61.7±2.45 |
| LE (%)                       | 60.3±2.94 | 66.7±2.41 | 72.1±1.65 | 71.7±0.49 |

*a*Data are averages of three independent experiments with standard deviations. doi:10.1371/journal.pone.0086064.t004

### Table 2. Comparison of different mass ratio between alginate and hyaluronate.

| Alginate:Hyaluronate (w/w) | 1:1 | 1:2 | 2:1 | 3:1 |
|----------------------------|-----|-----|-----|-----|
| Productivity (%)           | 58.2±1.91 | 50.1±1.19 | 61.4±0.74 | 67.9±1.33 |
| LE (%)                     | 60.7±0.74 | 55.4±1.54 | 64.5±2.64 | 70.9±1.71 |

*a*Data are averages of three independent experiments with standard deviations. doi:10.1371/journal.pone.0086064.t002
accumulative release of exenatide. Taken together, optimization of pH value, GTA amount, reaction temperature and reaction time produced satisfactory microspheres suitable for the encapsulation and release of exenatide.

2. Characterization of the microspheres

The loading efficiency for exenatide in the microspheres was 71.4 ± 2.57% (n = 3) and loading content was 2.98 ± 0.91% (n = 3). Same as the microspheres prepared by other materials, the present microspheres prepared with cross-linked alginate and hyaluronate also showed a globular structure (Fig. 1). However, they exhibited porous holes on the surface, which was significantly different from the microspheres prepared with alginate or hyaluronate alone [18,23]. The average diameter of the microspheres cross-linked for 0.5 h was approximately 4.1 μm, whereas the microspheres cross-linked for 2 h reached 15 μm. At the same time, the holes on the surface of the microspheres cross-linked for 2 h were much smaller than those cross-linked for 0.5 h and 1 h. Consequently, the time taken to release the drug from the microspheres cross-linked for 2 h was significantly longer than that for 0.5 h.

Because GTA has the potential to produce the cross-links between DNA and proteins, it could increase the frequency of airway symptoms in humans [24,25]. Therefore, residual GTA amount in the microspheres was determined by gas chromatography (GC). No residual GTA in the blank microspheres was observed from GC analysis (Fig. 2), suggesting that residual GTA was not an issue in the present microsphere preparation.

3. Accumulative releases of exenatide

The swelling pressure inside polymeric network can be enhanced due to electrostatic repulsion between charged moieties. Additionally, charge mobility can also be hindered by covalently cross-linked polymer [26]. As a result, higher osmotic pressure at internal gel and lower osmotic pressure at external solution could lead to the trend from solvent into the gel, and the cross-linked structure could be stable during the process of swelling [27]. Once the swelling degree reached the highest level, the microspheres would start to lose weight and the polymeric structure would begin to disintegrate [28]. In consistent with such a process, a close correlation between swelling ratio of the microspheres and released exenatide could be observed. In the group of microspheres cross-linked for 0.5 h, the swelling ratio was around 3.5 after 1 h switching from HCl solution (pH 1.2) to sodium phosphate saline (pH 7.4), and the accumulated exenatide concentration reached 80%. After another hour, complete release of exenatide was achieved at pH 7.4 (Fig. 3A). In the case of cross-linking for 1 h, swelling ratio reached approximately 15.3 in sodium phosphate saline (pH 7.4), and 31.3% exenatide was released at this time period (Fig. 3B). Very differently, the microspheres by cross-linking for 2 h reached a swelling ratio of nearly 25 after 1 h switching from pH 1.2 to pH 7.4. Meanwhile,

| Time (h) | 1N HCl | 5 ml GTA | 40°C |
|---------|--------|----------|------|
| 1       | 4.43 ± 1.41% | 5.67 ± 1.42% | 4.67 ± 1.89% |
| 2       | 11.63 ± 2.83% | 9.87 ± 1.99% | 10.5 ± 3.53% |
| 3       | 43.60 ± 2.76% | 40.53 ± 2.12% | 45.57 ± 1.07% |
| 4       | 64.60 ± 1.07% | 67.23 ± 1.91% | 66.37 ± 2.84% |
| 5       | 80.70 ± 1.07% | 85.53 ± 0.79% | 86.37 ± 2.32% |
| 6       | 92.43 ± 1.41% | 96.73 ± 2.35% | 96.47 ± 1.77% |
| 7       | 100.0 ± 2.49% | 100.0 ± 3.29% | 100.0 ± 2.97% |

*aData represent the percentage of released amount of exenatide from the microspheres by cross-linking for 0.5 h and are averages of three independent experiments with standard deviations.

doi:10.1371/journal.pone.0086064.t005
exenatide was only released less than 20%, and it took 12 h for the complete release (Fig. 3C). This comparison of cross-linking time indicated that cross-linking for 0.5 h exhibited the best swelling ratio and release profile.

4. In vivo PD and PK

As shown in Fig. 4, the group treated with subcutaneous injection of exenatide effectively lowered blood glucose within 1 h and kept effective for another 2 h, and then gradually returned to the original level. The glucose concentration in the blank microsphere group kept greater than 20 mmol/L after oral treatment. Similarly, there was no obvious effect to lower glucose level in the blank microspheres blended with free exenatide, indicating that free exenatide was completely destroyed in stomach. In contrary, the groups orally treated with exenatide-loaded microspheres exhibited remarkable glucose lowering effects, but different groups showed significant difference. The group of cross-linking for 0.5 h started to be effective at 2 h after oral administration and maintained the effectiveness for another 4 h, whereas the group of cross-linking for 1 h did not lower blood glucose until 8 h after oral administration. For the group of cross-linking for 2 h, the effect on glucose lowering was not observed, suggesting that the release speed of exenatide from highly cross-linked microspheres was very slow or the concentration of exenatide absorbed by intestine was too low to be effective. These results further confirmed that microspheres prepared by cross-linking of alginate and hyaluronate with a specific cross-linking degree could be a valuable vehicle for the oral delivery of exenatide. Moreover, compared to previous microspheres prepared by loading palmityl-acylated exendin-4 in porous poly-lactic-co-glycolic acid for long-acting hypoglycemic effect [29], the present microsphere system does not have the issue on the requirement to tolerate inhaling therapy by the patients.

To determine the pharmacokinetic parameters, the plasma exenatide concentration was measured after orally administrating exenatide-loaded microspheres. As shown in Fig. 5, there was no detectable exenatide in the group of orally administrating blank microspheres blended with free exenatide, whereas the plasma exenatide concentration reached its maximum in the subcutaneously treated group at 1 h post-injection with AUC value of

---

**Figure 2. GC analysis of residual GTA content in the microspheres.** (A) Partially enlarged GC chromatogram of 0.01% GTA. Top right corner shows the full chromatogram. (B) Partially enlarged GC chromatogram of blank microspheres (10 mg/ml). Top right corner shows the full chromatogram.

doi:10.1371/journal.pone.0086064.g002
Even though the maximum plasma exenatide concentration of the group orally treated with exenatide-loaded microspheres by cross-linking for 0.5 h appeared at 4 h after the treatment, this group behaved similarly to subcutaneous injection in terms of AUC value (3667 ± 19 pg h/ml). The relative

3614 ± 183 pg h/ml. Even though the maximum plasma exenatide concentration of the group orally treated with exenatide-loaded microspheres by cross-linking for 0.5 h appeared at 4 h after the treatment, this group behaved similarly to subcutaneous injection in terms of AUC value (3667 ± 19 pg h/ml). The relative
bioavailability of oral administration of this exenatide-loaded microsphere system was calculated to be 10.15±5.31%, which is close to the BAd reported by Nguyen et al [13]. Because of the relatively low bioavailability by oral delivery, a 10-fold increase of doing was required to achieve similar effects. Nevertheless, these PK parameters correlated well with the glucose-lowering effects mentioned above. The present PD/PK profiles demonstrated that the exenatide-loaded microspheres were stable and intact in the acidic environments of stomach, thereby promoting exenatide arriving at small intestine. Once entering small intestine, the microspheres begin to swell and release loaded exenatide. Moreover, it was noted that the size and shape of the microspheres are critical to the release and successful delivery of exenatide by oral route.

In the present study, the exenatide-loaded microspheres cross-linked for 0.5 h could effectively mimic the effects of subcutaneous injection of exenatide. Compared to reported nanoparticles and microspheres for oral delivery of exenatide [11,29], the present oral delivery system showed comparable effectiveness as subcutaneous injection, more desirable PK profile and convenient preparation and administration. Although the exenatide-loaded microspheres showed certain advantages for potential clinical application in the present study, the safety of the microspheres for human use requires further systemic evaluation.

Conclusion

After cross-linking of alginate and hyaluronate in the presence of exenatide, the exenatide-loaded microspheres were successfully developed as an oral delivery vehicle for exenatide. Through pH-responsive mechanism, this novel vehicle could keep intact in stomach and then release loaded exenatide in small intestine for absorption. The PD/PK profiles of the present oral vehicle exhibited the comparable effects on lowering blood glucose and kinetic behaviors as subcutaneous injection. Thus, the present study on the microspheres has the potential to substitute subcutaneous injection and provides an alternative therapeutic tool for diabetic patients.

Acknowledgments

Huanghai Biological Pharmaceutical Co. Ltd (Qingdao) for providing sodium algin.

Author Contributions

Conceived and designed the experiments: BZ YF YC. Performed the experiments: BZ YF. Analyzed the data: BZ DH YF NL. Wrote the paper: BZ DH YC.

References

1. Go¨ke R, Fehmann HC, Linn T, Schmidt H, Krause M, et al. (1993) Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide-1(7-36)-amide receptor of Insulin-secreting ß-cells. J Biol Chem 268:19630–19636.
2. Fehmann HC, Go¨ke R, Go¨ke B (1992) Glucagon-like peptide-1(7-37)/(7-36) amide is a new incretin. Mol Cell Endocrinol 85: C39–C44.
3. Moller DE (2001) New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414: 821–827.
4. Davidson MB, Bate G, Kirkpatrick P (2005) Exenatide. Nat Rev Drug Discov 4: 713–714.
5. Gedulin BR, Smith PA, Jodda CM, Chen K, Bhavaria S, et al. (2008) Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration. Int J Pharm 356: 231–239.
6. Fabo A (1998) Innovative strategies for the oral delivery of drugs and peptides. Trends Biotechnol 16: 152–157.
7. Hamman JH, Enslin GM, Kozet AF (2005) Oral delivery of peptide drugs barriers and developments. Bio Drugs 19: 163–177.
8. Ensink LM, Cone R, Hanes J (2012) Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliver Rev 64: 557–570.
9. Song HW, Sonaje K, Liao ZX, Hsu LW, Chang SY (2012) pH-responsive nanoparticles shelled with chitosan for oral delivery of insulin: from mechanism to therapeutic applications. Acc Chem Res 45: 619–629.
10. Moriuchi M, Peppas NA (2006) Is the oral route possible for peptide and protein drug delivery? Drug Discov Today 11: 905–910.
11. Jin CH, Chai SY, Son S, Kim TH, Um KA, et al. (2009) A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice. J Compil Therapeut 153: 172–177.
12. Gong N, Ma AN, Zhang JJ, Liao XS, Zhang YH, et al. (2011) Site-specific PEGylation of exenatide analogues markedly improved their gluco-regulatory activity. Brit J Pharmacol 163: 399–412.
13. Nguyen HO, Wey SP, Jaung JH, Sonaje K, Ho YC, et al. (2012) The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo. Biomaterials 32: 2673–2682.
14. Liu CV, Chan LW, Ching AL, Heng PWS (2006) Evaluation of sodium alginate as drug release mediator in matrix tablets. Int J Pharm 309: 25–37.
15. Esposito E, Menegatti E, Cortesi R (2005) Hyaluronan-based microspheres as tools for drug delivery: a comparative study. Int J Pharm 288: 35–49.
16. Appel EA, Loh XJ, Jones ST, Dreus CA, Scherman OA (2012) Sustained release of proteins from high water content supramolecular polymer hydrogels. Biomaterials 33: 4646–4652.
17. Funduraru G, Nastruzzi G, Carpo A, Deshieres J, Rinaudo M (1999) Physicochemical characterization of Ca-alginic microparticles produced with different methods. Biomaterials 20: 1427–1435.
18. Funduraru G, Esposito E, Mihai D, Carpo A, Deshieres J, et al. (1998) Preparation and characterization of Ca-algin microspheres by a new emulsification method. Int J Pharm 170: 11–21.
19. Gromhoft WR, Wesc SF (1998) Protein release from alginate matrices. Adv Drug Deliver Rev 31: 267–285.
20. Li M, Rouaud O, Poncelet D (2008) Microencapsulation by solvent evaporation: state of the art for process engineering approaches. Int J Pharm 363: 26–39.
21. Kulkarni AR, Soppimath KS, Aminabhavi TM, Dave AM, Mehat MH (2000) Glutaraldehyde crosslinked sodium alginate beads containing lipidic pesticide for soil application. J Control Release 63: 97–105.
22. Yrem CK, Lee KH (1998) Characterization of sodium alginate membrane crosslinked with glutaraldehyde in pervaporation separation. J Appl Polym Sci 67: 209–219.
23. Yun YH, Goetz DJ, Yellen P, Chen W (2004) Hyaluronic microspheres for sustained gene delivery and tissue-specific targeting. Biomaterials 25: 147–157.
24. Norback D (1998) Skin and respiratory symptomicrospheres from exposure to alkaline glutaraldehyde in medical services. Scand J Work Environ Health 14: 366–371.
25. Zeiger E, Gollapudi B, Spencer P (2005) Generic toxicity and carcinogenicity studies of glutaraldehyde—a review. Mutat Res 599: 136–51.
26. Maya DP, Hassarlet BP (2010) A quantitative analysis of alginate swelling. Carbohydr Polym 79: 1020–10207.
27. Bajpai SK, Sharma S (2004) Investigation of swelling/degradation behavior of alginate beads crosslinked with Ca+2 and Ba+2 ions. React Funct Polym 59:129–149.
28. Colinet I, Dulong V, Mocanu G, Piction L, Cerf DL (2009) New amphiphilic exendin-4 as a long-acting inhalation system for treating diabetes. Biomaterials 32: 1685–1693.

PLOS ONE | www.plosone.org 7 January 2014 | Volume 9 | Issue 1 | e86064